Introduction
In recent years, prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT), mostly bound to gallium-68 ( 68 Ga) , has significantly emerged as the diagnostic tool of choice for primary prostate cancer staging and as an imaging modality for biochemical recurrence. [1] [2] [3] [4] However, according to recent guidelines, multiparametric magnetic resonance imaging MRI (mpMRI) should be the modality of choice for initial local staging and for assessment of local recurrence. [5] [6] [7] In addition, although serving as a comparable diagnostic tool for primary staging and as a favorable imaging modality for local recurrence, 68 Ga-PSMA PET/CT has the disadvantage of bladder activity, which can be a problem for local recurrence detection. report, we evaluated the advantages of PSMA PET/CT to evaluate a patient with biochemical recurrence and unclear findings on mpMRI.
Case Report
In January 2017, prostate cancer (PCa) was diagnosed in a 48-year-old patient. The PCa was Gleason score 3þ4 and International Society of Urological Pathology grade 2. The patient underwent radical prostatectomy. The radical prostatectomy specimen revealed pathologic stage T2cN0. The clinical M stage was M0. No adjuvant radiotherapy was administered. The prostatespecific antigen (PSA) level decreased from 7.8 ng/mL preoperatively to 0.1 ng/mL after surgery, indicating biochemical recurrence. Six months later, the patient was referred to our clinic, with a request for imaging using mpMRI owing to an elevated PSA level of 0.3 ng/mL. MRI did not detect any distinct suspicious local tumor growth or lymph node metastases ( Figure 1 ). mpMRI was conducted as described previously using state-of-the-art high b values (b ¼ 0, 1000, and 1500 s/mm 2 ) and T1-weighted dynamic contrast enhancement with 50 time measurements. A smaller contrast-enhanced nodule close to the bladder (Denonvillier fascia) on the right side was noted. However, the certainty of the boardcertified radiologist was low, and the finding was reported as unclear. The apparent diffusion coefficient was moderately (Figure 2) . No metastatic lymph nodes or distant metastases were detected on the PSMA PET/CT scan. Therefore, local stereotactic radiotherapy was initiated, with a PSA decrease confirmed during the treatment.
Discussion
Up to 40% of patients undergoing radical prostatectomy for primary treatment of PCa will develop biochemical recurrence. [13] [14] [15] [16] [17] For these patients, precise localization of recurrent disease and accurate restaging is crucial for adequate treatment selection. However, conventional imaging modalities such as CT or MRI have some limitations in the detection of local disease. 18 The role of PET/CT has gradually increased in importance for prostate cancer patients with biochemical relapse.
18 F-choline and 11 C-choline as markers of membrane cell proliferation are radiotracers currently widely used in clinical practice. However, some studies have reported low sensitivity and specificity, especially in patients with low PSA values. 19 PSMA ligands have been reported to have greater sensitivity and specificity than the choline derivate. 20 Nevertheless, the most significant advantage of 68 Ga-PSMA-11
PET/CT is the sensitive detection of lesions even at low PSA levels, even small lymph node metastases, and bone and visceral metastases owing to the low background signal. 4, 20 Also, 68 Ga-PSMA-11
ligands have the disadvantage in the assessment of small local recurrences of excretion by way of the kidneys and high accumulation in the urinary bladder. 10 18 F-PSMA-1007 is an attractive alternative to the Ga-PSMA radioligand, because it has demonstrated better energy and fast, nonurinary background clearance, which greatly improves evaluation of the former left prostatic bed. 11 An SUVmax of 40 and 100 in the bladder for 68 Ga-PSMA-617 and 68 Ga-PSMA-11 has been reported, respectively. 3, [21] [22] [23] In contrast, the content of the urinary bladder was an SUVmax of 5 for 18 F-PSMA-1007. 11 Performing 18-F-PSMA-1007 PET/CT at very low PSA levels potentially allows for more effective salvage treatment, because the prognosis is improved by the initiation of treatment before the PSA level has exceeded 0.5 ng/mL. 24 
Conclusion
Low urinary clearance of 18 F-PSMA-1007 for PET/CT imaging provides additional diagnostic value in the case of local recurrence after radical prostatectomy that was considered unclear using standard mpMRI.
